Home>Topics>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. AbbVie: Growth Story Or Patent Expiration Nightmare?

    Headlines

    Thu, 28 Aug 2014

    largest publicly traded drug manufacturer in the world, behind giants such as AstraZeneca (NYSE: AZN ), GlaxoSmithKline (NYSE: GSK ), and Pfizer (NYSE: PFE ). Humira Is AbbVie's Biggest Winner AbbVie generated 67% of its 2nd-quarter

  2. Gilead: Let's Make A Deal

    Headlines

    Thu, 28 Aug 2014

    market cap) than many familiar pharma names including Sanofi, Lilly, AbbVie, Bayer AG, Bristol-Myers-Squibb, GlaxoSmithKline , AstraZeneca, Novo Nordisk, and Amgen. Gilead is rapidly approaching the market cap of the two largest US pure

  3. Ebola cases accelerating

    Headlines

    Thu, 28 Aug 2014

    Ebola Vaccine in Preclinicals; BioCryst Pharmaceuticals (NASDAQ: BCRX ): BCX4430 in Preclinicals; GlaxoSmithKline (NYSE: GSK ): Ebola Vaccine in Preclinicals; Nanoviricides (NYSEMKT: NNVC ): NV-INF-1 in Preclinicals; Inovio

  4. GSK Ebola vaccine fast-tracked into U.S., UK and African trials

    Headlines

    Thu, 28 Aug 2014

    LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.

  5. Glaxo's ebola vaccine to begin human clinical trials shortly

    Headlines

    Thu, 28 Aug 2014

    announcement by U.S. health officials today will state that a human study for the Ebola vaccine made by GlaxoSmithKline (NYSE: GSK ) will begin within a couple of weeks instead of later this year as the company originally estimated. Glaxo's

  6. Ebola vaccine from GSK to begin U.S. clinical trials within weeks-sources

    Headlines

    Wed, 27 Aug 2014

    27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people

  7. Tekmira +4% on takeover rumors; Shire, Glaxo said to have interest

    Headlines

    Wed, 27 Aug 2014

    treatment for the deadly ebola virus. Rumors suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share

  8. Novo Nordisk: The Case For Predictability In Earnings

    Headlines

    Tue, 26 Aug 2014

    diabetes care market. With the share price up more than 20% year-to-date, Novo Nordisk has now surpassed GlaxoSmithKline (NYSE: GSK ) in market capitalization. The short story about earnings Over the past ten years, Novo Nordisk's annualized

  9. Expanded label for Promacta

    Headlines

    Tue, 26 Aug 2014

    The FDA approves a label expansion for GlaxoSmithKline 's ( GSK +0.3% ) Promacta ( eltrombopag ) for once-daily use in patients with severe aplastic anemia who have had an insufficient

  10. Gene Tech rallies after NC court order

    Headlines

    Tue, 26 Aug 2014

    North Carolina district court order denying a motion by GlaxoSmithKline ( GSK +0.5% ) to dismiss Genetic Tech's primary non-coding ..... Genetic Tech filed the suit in 2011. On June 27, 2014 GSK moved to have Genetic Tech's complaint dismissed

« Prev12345Next »
Content Partners